Genentech reports PML case for Raptiva

Genentech (NYSE:DNA) issued a "Dear Healthcare Professional" letter for Raptiva efalizumab to report a case of progressive multifocal leukoencephalopathy (PML) in a 70-year-old patient with chronic plaque psoriasis. The company said it will work with FDA to update the label and determine if further action is needed. ...